ABSTRACT
The survey was conducted in Shaoxing city from January 2019 to January 2021 among 150 residents aged ≥ 60 years with mild cognitive impairment from Shaoxing People's Hospital and its subordinate branches. The swallowing function was evaluated by eating evaluation questionnaire-10 (EAT-10), and dysphagia (EAT-10 score ≥ 3) was identified in 92 subjects with a prevalence rate of 61.3% (dysphagia group) and other 58 residents without dysphagia was set as normal group. There were significant differences in age, educational level, diet type, history of stroke, history of choking, Mini-mental State Examination (MMSE) score, masticatory function score, the number of drug types, self-care ability (Barthel score) in Activities of Daily Living (ADL) scale between dysphagia group and normal group (all P<0.05). Multivariate logistic analysis showed that age (≥ 80 years old), educational level (junior middle school and below), history of stroke, history of choking cough, MMSE score (<23 points), Barthel score (≤ 60 points), masticatory function score (>3 points) and the number of drug types (≥ 3 kinds) were independent risk factors of swallowing disorder in elderly with mild cognitive impairment; and the type of diet (common diet) was the protective factor. It is suggested that the prevalence of dysphagia in community-dwelling elderly with mild cognitive impairment is high, and necessary measures should be taken to intervene according to its risk factors.
ABSTRACT
Objective To investigate the correlation between EEG severity and secondary epilepsy in elderly patients with cerebral infarction.Methods 128 cases with cerebral infarction were selected as the research subjects. According to whether the patients happened secondary epilepsy,they were divided into the observation group (65 cases) and the control group (63 cases).The difference of EEG severity between the two groups was compared,and its correlation with secondary epilepsy was analyzed.Results There were 18 cases (27.69%)in the observation group graded as moderate differences,which was significantly higher than that in the control group of 12 cases (19.05%), the difference was statistically significant (χ2 =4.43,P =0.04).There were 23 cases (35.38%)in the observation group graded as severe differences,which was significantly higher than that in the control group of 9 cases (13.85%),the difference was statistically significant (χ2 =6.51,P =0.01 ).There were 21 cases(32.31%)of EEG changes of observation group being only diffuse abnormalities forms,which was significantly higher than that of the control group of 11 cases(17.46%),the difference was statistically significant (χ2 =4.18,P =0.04).There were 28 cases(43.08%)of EEG changes of the observation group being both focal abnormalities and diffuse abnor-malities forms,which was significantly higher than that of the control group of 14 cases(22.22%),the difference was statistically significant (χ2 =5.40,P =0.02).Compared open -closed test,hyperventilation provocation test results of the observation group being abnormal or not fit with the control group,the difference was not statistically significant (P >0.05).Conclusion According to the classification of EEG,EEG changes and EEG related tests to determine the severity of EEG.The more severe EEG,the greater the possibility of secondary epilepsy happen in patients with cerebral infarction.
ABSTRACT
Objective To analyze the efficacy of rosuvastatin on the patients with hyperlipidemia and hypertension.Methods From March 2011 to June 2012,112 cases with hyperlipidemia and hypertension in our hospital were enrolled in this study.Patients were randomly divided into treatment group and control group (56 patients,each).Patients in control group were treated with oral amlodipine 5 mg/d.Patients in treatment group were treated with oral rosuvastain 10 mg/d and oral amlodipine 5 mg/d.One month after the treatment,the levels of blood pressure,total cholesterol (TC),tryglyceride (TG),low density liporotein (LDL-C),high density lipoprotein cholesterol (HDL-C),high sensitivity C-reactive protein (hsCRP) were determined.The occurrence of adverse effects were observed.Results One month after treatment,systolic blood pressure and diastolic blood pressure were significantly decreased in both two groups compared with pre-treatment [Control group:(135.2±9.51)mm Hgvs.(59.2±7.3)mm Hg,(88.8±5.2)mm Hg vs.(99.5±8.3)mm Hg,t=4.95,2.87; Treatment group:(130.2±5.5)mm Hg vs.(160.3±9.3)mm Hg,(86.7± 10.2)mm Hg vs.(99.7±8.3)mm Hg,t=5.03,2.94,all P＜0.01],but more declines were found in treatment group than in control group(t=3.96,3.42,both P＜0.001).The levels of LDL-C,TG and TC were significantly decreased in both two groups compared with pre-treatment [Control group:(2.64±0.72)mmol/L vs.(3.97±0.84)mmol/L,(1.89±0.25)mmol/L vs.(2.56±0.45)mmol/L,(4.23±0.56)mmol/L vs.(7.36±0.48)mmol/L,t=2.58,3.03,2.36,P=0.013,0.004,0.022;Treatment group:(1.75 ± 0.68) mmol/L vs.(3.85 ± 0.79) mmol/L,(1.71 ± 0.18) mmol/L vs.(2.63±0.42)mmol/L,(3.18±0.47)mmol/L vs.(7.20±0.56)mmol/L,t=2.77,3.16,2.59,P=0.008,0.003,0.012,respectively],but more declines were observed in treatment group than in control group(t=6.73,4.37,10.70 respectively,all P＜0.05).The HDL-C concentrations were increased in both two groups compared with pre-treatment [Control group:(0.97±0.26)mmol/L vs.(0.75±0.31)mmol/L,t=2.89,P=0.006; Treatment group:(1.09±0.23)mmol/L vs.(0.72±0.24)mmol/L,t=3.01,P=0.004],but more increment were observed in treatment group than in control group(t=2.59,P＜0.05).The hsCRP concentration was significantly reduced in treatment group compared with pre-treatment [(1.32±0.17) mg/L vs.(4.97±0.13) mg/L,t=4.40,P＜0.001].There were no significant differences in liver and kidney function between the two groups.Serious adverse effects were not found.Conclusions Rosuvastatin combined with routine antihypertensive therapy can effectively decrease the levels of serum LDL-C,TG,hsCRP; increase serum HDL-C concentration and blood pressure can be effectively controlled.